A Quiet Reflection Before the Next Dawn: When Science Meets the Human Heart”

“A Quiet Reflection Before the Next Dawn: On Science and the Human Heart”

Dear Friends,

I could not sleep the entire night.

As I lay awake in the quiet stillness before dawn, I found myself wondering what subject I should write next in my blog. Many ideas came and went, but none seemed to settle comfortably in my mind.

Just before Chap Goh Meh ended at midnight, the final evening of the Chinese New Year celebrations — I took out my German violin, the one that cost me RM 65,000, and played ten different Chinese New Year songs.

To my ears, they sounded quite horrible.

I have not played my violin for at least eight months. When one loses daily practice, the fingers lose their memory. The delicate precision of fingering falters. Intonation suffers. The bow no longer glides with confidence. And with my poor eyesight, I struggled to read the musical notes on the sheet music, those little black symbols that look like “taugay” or bean sprouts to anyone without musical training.

In my younger days, I passed Grade 6 in violin performance and also in music theory under the Associated Board of the Royal Schools of Music (ABRSM) in England. That foundation has always remained precious to me.

But a violinist rarely plays alone. A violinist is usually accompanied by a pianist — or better still, surrounded by fellow violinists within an orchestra, blending with violas, cellos, double basses, woodwinds, brass, and percussion. Music, especially orchestral music, is a communal experience.

Years ago, I was a member of the Symphony Club of the Malaysian Philharmonic Orchestra. I played together with other violinists in symphonic settings. The collective sound, the harmony, the shared breathing of the orchestra — that was music in its full glory. I have since lost touch for many years.

That is why, perhaps, it sounded so harsh to me, playing alone after months of neglect, without accompaniment, without the warmth of an orchestra.

I own four violins. This German violin is the most expensive of them all, almost the cost of a small car. Yet the price of an instrument does not guarantee beauty of sound. Only disciplined practice, sensitive listening, and musical companionship can do that.

If you ask me honestly, I would say I prefer being a violinist rather than being a research scientist or a doctor. Medicine and research were my profession. Music is my love.

Just like astronomy — another passion of mine. Even after retirement, I studied astronomy at Oxford, simply for the joy of learning and looking up at the heavens.

Perhaps life is not only about achievement, titles, or productivity. Perhaps it is also about returning, again and again, to the things that make our hearts quietly happy, even if, at times, they sound imperfect.

If you would like to read more about my reflections on music and the violin, do visit my earlier write-up:

“The Joy of Being A Violinist”

 

https://scientificlogic.blogspot.com/search?q=Music+and+violin+

 

With warm regards in the stillness of this pre-dawn hour

From Molecule to Medicine: The Hidden Army of Scientists Behind Every New Drug

I have already written an article on the various scientists involved in the development of new drugs here in this link:

https://scientificlogic.blogspot.com/2025/04/the-immense-contributions-of-scientists.html

It was written and published in this blog of mine on Wednesday, April 9, 2025

Yesterday, on 2^nd March 2026 - towards the end of Chinese New Year of the Horse we get readers in WhatsApp chat group asking me almost the same issue on who are the scientists who develop drugs for medical doctors to prescribe for their patients?

Let me on this last day of CNY in Chinese Hokkein dialect  called “Chap Goh Mei” in  rewrite my article in a different language style and in greater technical depths  for  doctors, biomedical scientist, their patients and also for curious,  but highly knowledgeable and intelligent ordinary readers. Below is my rewritten version entitled:  

 

From Molecule to Medicine: The Hidden Army of Scientists Behind Every New Drug

Technical Abstract for Medical Doctors and Biomedical Scientists.

 

Technical Abstract

 

Modern drug discovery and development is a multidisciplinary, capital-intensive, and highly regulated enterprise requiring 10–15 years of coordinated scientific effort and investments frequently exceeding several billion US dollars per approved therapeutic agent. The process encompasses target identification and validation, hit discovery, lead optimization, preclinical pharmacology and toxicology, clinical development (Phases I–III), regulatory review, large-scale manufacturing, and post-marketing pharmacovigilance.

This article provides a comprehensive overview of the scientific ecosystem underlying pharmaceutical innovation, detailing the expertise, methodologies, regulatory frameworks, computational tools, and educational backgrounds of the diverse specialists involved — including molecular biologists, medicinal chemists, pharmacologists, toxicologists, pharmacokineticists, formulation scientists, analytical chemists, biostatisticians, clinical investigators, pharmaceutical engineers, quality assurance professionals, regulatory affairs experts, and emerging artificial intelligence scientists. Emphasis is placed on the translational continuum from molecular design to population-level therapeutic deployment, highlighting the scientific rigor, attrition rates, compliance standards (GLP, GMP, GCP), and technological platforms that collectively enable safe and effective drug approval.

 

Main text for All Readers:

 

When a new medicine appears in a pharmacy, it looks deceptively simple,  a tablet in a blister pack, a vial for injection, a capsule in a bottle. Yet behind that small object lies 10 to 15 years of work, thousands of experiments, regulatory scrutiny across continents, and investments that often exceed several billion US dollars. What the public rarely sees is the vast multidisciplinary team of scientists whose combined expertise makes modern drug development possible.

Drug discovery and development is not the work of a lone genius in a laboratory. It is a coordinated scientific orchestra in which chemists, biologists, pharmacologists, toxicologists, clinicians, engineers, statisticians, and regulatory experts each play indispensable roles.

The journey begins in discovery laboratories, often long before a compound has a name.

In the earliest phase, disease biologists and molecular biologists identify a therapeutic target, typically a protein, receptor, enzyme, gene product, or signalling pathway believed to drive a disease. Their work relies on genomics, proteomics, transcriptomics, CRISPR gene editing, and advanced microscopy. They use software tools such as bioinformatics platforms (BLAST, Gene Ontology tools), pathway analysis systems (Ingenuity Pathway Analysis), and molecular databases to understand disease mechanisms at the cellular and molecular levels.

Once a viable target is identified, medicinal chemists enter the scene. These are specialists in organic and pharmaceutical chemistry who design and synthesize new chemical entities. Their task is intellectually demanding: they must design molecules capable of binding precisely to the biological target while maintaining favourable physicochemical properties such as solubility, stability, and membrane permeability. They use computer-aided drug design software such as Schrödinger Suite, MOE (Molecular Operating Environment), AutoDock, and molecular dynamics simulation tools. High-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry are essential laboratory instruments in their daily work.

Parallel to medicinal chemists, computational chemists and structural biologists use X-ray crystallography, cryo-electron microscopy, and AI-driven protein modelling tools to visualize target structures at atomic resolution. Structure-based drug design allows refinement of molecules into optimized “lead compounds.”

After promising compounds are synthesized, pharmacologists test them in vitro and in vivo. Pharmacologists study how drugs interact with biological systems and determine their mechanisms of action. Using cell-based assays, receptor binding studies, and animal models, they measure potency, efficacy, selectivity, and functional outcomes. Laboratory techniques include ELISA, Western blotting, flow cytometry, and electrophysiology. Their software tools often include GraphPad Prism for dose-response curves and statistical analysis platforms.

Simultaneously, pharmacokineticists — experts in drug metabolism and pharmacokinetics (DMPK) — examine how the body handles the compound. They study absorption, distribution, metabolism, and excretion (ADME). Using in vitro liver microsomes, hepatocyte assays, and in vivo animal studies, they determine half-life, bioavailability, clearance rates, and metabolic pathways. They frequently use modeling software such as Phoenix WinNonlin and physiologically based pharmacokinetic (PBPK) modeling platforms like GastroPlus or Simcyp.

Toxicologists then perform rigorous safety assessments. No matter how effective a molecule may be, unacceptable toxicity ends its development. Toxicologists conduct acute, sub-chronic, and chronic toxicity studies, genotoxicity testing, reproductive toxicity studies, and carcinogenicity assessments in animal models under Good Laboratory Practice (GLP) standards. Histopathology, clinical chemistry analysis, and organ system monitoring are routine. Safety pharmacology also examines effects on the cardiovascular, respiratory, and central nervous systems. Specialized assays such as hERG channel testing evaluate cardiac arrhythmia risk.

Once a compound demonstrates acceptable efficacy and safety in preclinical studies, it enters the clinical phase. Here, clinical research physicians and clinical pharmacologists design and oversee human trials. Phase I trials test safety and dosing in healthy volunteers. Phase II trials explore efficacy and dose-ranging in patients. Phase III trials involve large patient populations to confirm effectiveness and monitor adverse events.

Clinical research scientists coordinate trial logistics across hospitals and countries. Biostatisticians design the study protocols, calculate sample sizes, define endpoints, and perform complex statistical analyses to determine whether observed benefits are significant and clinically meaningful. They rely heavily on statistical software such as SAS, R, and SPSS. Data managers ensure data integrity, while clinical operations teams ensure compliance with Good Clinical Practice (GCP).

Throughout clinical development, pharmacovigilance experts monitor safety signals. They analyse adverse event reports and conduct risk-benefit assessments. After regulatory approval, this monitoring continues in Phase IV post-marketing surveillance.

While clinical trials proceed, formulation scientists work on transforming the active molecule into a usable medicine. A compound must not only be effective — it must remain stable, bioavailable, manufacturable, and convenient for patients. Formulation scientists determine excipient compatibility, optimize dissolution rates, control-release mechanisms, and ensure shelf stability. Techniques include differential scanning calorimetry (DSC), powder X-ray diffraction, and stability chambers under ICH guidelines.

Analytical chemists develop and validate methods to measure drug purity, potency, degradation products, and impurities at every stage. They ensure compliance with pharmacopeial standards (USP, EP, JP). Their instruments include HPLC, GC-MS, LC-MS/MS, UV spectroscopy, and capillary electrophoresis. Method validation follows strict regulatory requirements for accuracy, precision, specificity, and robustness.

When a drug approaches commercialization, pharmaceutical engineers and chemical engineers design large-scale manufacturing processes. Scaling up from milligram laboratory batches to multi-ton industrial production is a highly complex endeavor. Process engineers optimize reaction conditions, ensure reproducibility, manage heat transfer and solvent recovery, and design reactors compliant with Good Manufacturing Practice (GMP). Increasingly, they use process analytical technology (PAT) and continuous manufacturing systems.

Quality control scientists test every batch produced. Quality assurance teams oversee documentation, audits, and regulatory inspections. Regulatory affairs specialists compile massive dossiers, sometimes exceeding hundreds of thousands of pages — for submission to agencies such as the U.S. FDA, EMA in Europe, and other global regulatory authorities. They ensure compliance with international standards, interpret regulatory guidelines, and manage communication between the company and authorities.

Educationally, these professionals are highly trained. Medicinal chemists typically hold PhDs in organic chemistry or pharmaceutical sciences. Pharmacologists and toxicologists often hold PhDs or MD / PhDs. A PhD in Medicine is far, far more advanced and sophisticated  than just an ordinary MD. 

Clinical investigators are medical doctors with research training. Biostatisticians possess advanced degrees in statistics or biostatistics. Pharmaceutical engineers are trained in chemical or biochemical engineering. Regulatory affairs professionals may come from pharmacy, law, or biomedical science backgrounds with specialized regulatory certification.

Increasingly, artificial intelligence and machine learning specialists are joining drug development teams. AI models assist in target identification, virtual screening, toxicity prediction, and clinical trial optimization. Software environments such as Python, TensorFlow, and machine learning frameworks are becoming integral tools.

Thus, the creation of a single medicine represents the coordinated labour of hundreds, sometimes thousands  of highly specialized professionals over more than a decade. Many promising compounds fail along the way. Only a small fraction of molecules entering preclinical testing ever reach approval. This high attrition rate contributes significantly to the enormous cost of drug development.

Yet despite the complexity and cost, this multidisciplinary enterprise has given humanity antibiotics, vaccines, targeted cancer therapies, immunotherapies, antivirals, and life-saving biologicals and biosimilars. Each pill carries within it not merely chemical ingredients, but the cumulative knowledge of molecular biology, organic chemistry, physiology, engineering, statistics, ethics, and regulatory science.

Happy and A Blessed  Chap Goh Mei to all my interested readers

The Lady of the Moon in Chinese mythology is called  Change's  (嫦娥, pronounced Cháng-é). 

Here are the key details about her name and story:

Original Name: She was originally called Heng'e (姮娥, Héng'é), but her name was changed to Chang'e due to a naming taboo during the reign of Emperor Wen of Han. She is said to live in the Guanghan Palace (廣寒宮, Vast-Cold Palace) on the moon. She is accompanied by the Jade Rabbit (玉兔, Yù Tù), who pounds the elixir of life, and sometimes a toad.

The Year of the Rabbit is also my year of Birth in Batu Pahat, Johore, Malaya, then called

Look up for her tonight on Chap Goh Mei, shinning in all her glory. 

Coincidentally, there is a lunar eclipse tonight, but the moon is below the horizon part of time over Kuala Lumpur and Malaysia. By the time the moon at maximum eclipse rises over the horizon in Malaysia, it is 7:33:46 pm. The full eclipse ends at 8:02:49 pm and the eclipse  penumbra phase ends at 10:23:06 pm. Only certain parts of the world  the full lunar eclipse is visible from beginning to finish.     

-   Lim ju boo

3^rd March, 2036

Technical Paper on Immunotherapy for Cancers vs Cancer Vaccines

Immune Checkpoint Inhibitors Versus Cancer Vaccines:

Mechanistic Distinctions, Immunological Foundations, and Implications for Preventive Oncology

Lim JB¹ & Sage P²
¹Independent Medical Scholar / Researcher
²Department of Theoretical Immunology

 

Abstract

Cancer immunotherapy has transformed modern oncology by harnessing endogenous immune mechanisms to eliminate malignant cells. Among its most successful modalities are immune checkpoint inhibitors (ICIs), including programmed death-1 (PD-1) pathway blockers such as Pembrolizumab. Concurrently, therapeutic cancer vaccines aim to induce tumour-specific immune responses through antigen-directed priming. Although frequently grouped under the umbrella of immunotherapy, these modalities differ fundamentally in mechanism, immunological impact, and suitability for preventive applications. This review examines the biological basis of immune checkpoint inhibition and cancer vaccination, emphasizing mechanisms of central and peripheral tolerance. We analyse why checkpoint inhibitors, despite their therapeutic efficacy, are biologically unsuitable for use in healthy individuals as preventive agents. The distinction between immune amplification and immune education is critical for guiding future strategies in immuno-prevention and maintaining the balance between anti-tumour immunity and self-tolerance.

Executive Summary

Cancer immunotherapy has fundamentally transformed modern oncology by shifting treatment strategies from direct cytotoxic destruction of tumour cells to modulation of the host immune system. Among the most impactful advances are immune checkpoint inhibitors (ICIs), particularly programmed death-1 (PD-1) pathway blockers such as Pembrolizumab. These agents restore anti-tumour T-cell activity by disrupting inhibitory signalling pathways that normally maintain immune tolerance.

However, checkpoint inhibition and cancer vaccination represent mechanistically distinct immunological strategies. Checkpoint inhibitors amplify immune activity by releasing peripheral inhibitory control mechanisms such as PD-1 and CTLA-4. In contrast, cancer vaccines aim to induce antigen-specific immune responses through targeted priming and immunological memory formation.

This distinction carries profound implications. While checkpoint inhibitors have demonstrated significant survival benefits across multiple malignancies, their mechanism inherently disrupts immune tolerance and may precipitate immune-related adverse events, including organ-specific autoimmune disorders. The same biological mechanism that enables tumour eradication also increases the risk of collateral tissue damage.

A question a medical specialist colleague asked whether checkpoint inhibitors could be used prophylactically in healthy individuals to stimulate anti-cancer immunity raises critical immunological and ethical concerns. Unlike vaccines, checkpoint inhibitors do not introduce tumour-specific antigens or enhance immune precision. Rather, they remove regulatory restraints that are essential for preventing autoimmunity. In the absence of active tumour antigen stimulation, broad immune activation may lead to loss of peripheral tolerance without conferring meaningful protective benefit.

Preventive oncology requires enhancement of immune surveillance while preserving immunological equilibrium. Based on current mechanistic understanding, immune checkpoint blockade is biologically unsuitable as a generalized preventive strategy in healthy populations. The contrast between immune amplification and immune education underscores the need for precision in future immuno-preventive research.

Keywords

Cancer immunotherapy; immune checkpoint inhibitors; PD-1; pembrolizumab; cancer vaccines; immune tolerance; autoimmunity; immuno-prevention

 

1. Introduction

The development of cancer immunotherapy represents a paradigm shift in oncology. Rather than directly targeting tumour cells through cytotoxic agents, immunotherapy modulates host immune responses to enhance tumour recognition and destruction. Major modalities include immune checkpoint inhibitors (ICIs), adoptive cell therapies, monoclonal antibodies, antibody-drug conjugates, oncolytic viral therapy, therapeutic cancer vaccines, and cytokine-based immunomodulators.

While these approaches share the objective of enhancing anti-tumour immunity, their mechanisms differ substantially. In particular, immune checkpoint inhibitors and cancer vaccines operate at distinct regulatory levels of immune activation. This distinction becomes critically important when considering theoretical preventive applications in individuals without established malignancy.

2. Immune Checkpoint Inhibition: Mechanistic Foundations

2.1 Physiological Role of Immune Checkpoints

T-cell activation is tightly regulated by stimulatory and inhibitory signals. Two principal inhibitory pathways are cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1).

CTLA-4 regulates early T-cell activation within secondary lymphoid organs by competing with CD28 for B7 ligands on antigen-presenting cells. PD-1, in contrast, primarily regulates T-cell activity in peripheral tissues. Upon engagement with its ligands PD-L1 or PD-L2, PD-1 signalling suppresses T-cell proliferation, cytokine production, and cytotoxic function.

These checkpoints are essential for maintaining peripheral tolerance and preventing immune-mediated tissue injury.

2.2 Tumour Immune Evasion

Many tumour cells upregulate PD-L1 expression, thereby engaging PD-1 on tumour-infiltrating lymphocytes and inducing T-cell exhaustion. This immune evasion strategy allows malignant cells to persist despite antigenic recognition.

Checkpoint inhibitors disrupt this inhibitory interaction, restoring cytotoxic T-cell function.

2.3 Clinical Application of Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody targeting PD-1. By blocking PD-1 receptor engagement, it enhances T-cell-mediated tumour destruction.

It has received regulatory approval for multiple malignancies, including:

(a) Melanoma

(b) Non-small cell lung cancer

(c) Head and neck squamous cell carcinoma

(d) Triple-negative breast cancer

(e) Classical Hodgkin lymphoma

(f) Microsatellite instability-high (MSI-H)

(g) or mismatch repair-deficient tumours (tumour-agnostic approval)

Its tumour-agnostic approval marked a milestone in biomarker-driven oncology, reflecting a shift from organ-based to molecularly guided therapy.

3. Immunological Tolerance: Central and Peripheral Control

3.1 Central Tolerance

During thymic development, T cells undergo negative selection to eliminate strongly self-reactive clones. This establishes central tolerance but is not absolute.

Autoreactive T cells may escape deletion and enter peripheral circulation.

3.2 Peripheral Tolerance

Peripheral tolerance mechanisms prevent escaped autoreactive T cells from causing pathology. These include:

• Regulatory T cells (Tregs)
• Anergy induction
• Immune checkpoint pathways such as PD-1

PD-1 signaling therefore serves a physiological role in restraining self-reactivity.

 

4. Immune-Related Adverse Events and Loss of Tolerance

Checkpoint inhibition disrupts peripheral tolerance and may precipitate immune-related adverse events (irAEs). Documented toxicities include:

• Pneumonitis
• Colitis
• Hepatitis
• Nephritis
• Hypophysitis
• Thyroiditis
• Insulin-dependent diabetes mellitus
• Inflammatory arthritis

These toxicities are mechanistically linked to enhanced autoreactive T-cell activation rather than off-target drug toxicity.

In patients with advanced malignancy, this risk may be justified. In individuals without cancer, such risk would lack ethical justification.

5. Cancer Vaccines: Antigen-Specific Immune Education

Therapeutic cancer vaccines operate through antigen-specific immune priming. By introducing tumour-associated or tumour-specific neoantigens, vaccines promote:

1. Antigen uptake by dendritic cells

2. Presentation via major histocompatibility complex (MHC) molecules

3. Activation of naïve T cells

4. Clonal expansion of antigen-specific cytotoxic T lymphocytes

5. Development of immunological memory

This strategy enhances specificity rather than indiscriminate activation.

Vaccines do not remove immune checkpoints globally; instead, they provide targeted immune instruction.

6. Conceptual Distinction: Immune Amplification Versus Immune Education

Checkpoint inhibitors amplify immune intensity by removing inhibitory signalling. Cancer vaccines increase immune specificity through antigen-directed priming.

This distinction is fundamental.

Without antigenic direction, checkpoint inhibition lacks precision. In the absence of tumour antigen stimulation, broad immune activation risks self-tissue damage without therapeutic benefit.

7. Implications for Preventive Oncology

The concept of administering checkpoint inhibitors prophylactically in healthy individuals has been suggested in theoretical discussions. However, such an approach is biologically unsound for several reasons:

1. Absence of target antigen stimulation

2. Disruption of peripheral tolerance

3. Risk of irreversible autoimmune disease

4. Unfavourable risk-benefit ratio

Research into immuno-prevention is ongoing in high-risk populations (e.g., hereditary cancer syndromes or premalignant lesions), but these investigations occur under controlled clinical trial conditions. These individuals are not immunologically “healthy” controls.

Preventive strategies must preserve immune tolerance while enhancing tumour surveillance. Checkpoint blockade intrinsically compromises tolerance.

 

8. Ethical Considerations

The ethical principle of proportionality in medicine requires that therapeutic risk be justified by disease burden. In metastatic cancer, immune-related toxicities may be acceptable. In asymptomatic individuals, exposure to systemic immune dysregulation would be medically indefensible.

 

A Summary for Non-Technical Readers:

Immune checkpoint inhibitors such as Pembrolizumab have revolutionized oncology by restoring anti-tumour immunity through release of peripheral inhibitory control. Their success reflects the power of immune amplification in established malignancy.

However, checkpoint inhibitors and cancer vaccines are mechanistically distinct. Vaccines educate the immune system with antigen-specific precision. Checkpoint inhibitors remove regulatory restraints, increasing immune force but risking autoimmunity.

Preventive oncology requires strategies that enhance immune surveillance without disrupting tolerance. Based on current immunological understanding, checkpoint inhibition is unsuitable for use in healthy individuals as a preventive modality.

The immune system is a finely regulated network. Its therapeutic manipulation must respect the equilibrium between activation and tolerance upon which physiological integrity depends.

Cancer vaccines are a specific type of immunotherapy designed to teach the immune system to recognize and destroy cancer cells by targeting unique antigens. While broader immunotherapies (like checkpoint inhibitors) "release the brakes" on the immune system, vaccines actively "train" it. Vaccines generally offer higher specificity and fewer, but sometimes different, side effects compared to broader, more toxic immunotherapy.

References

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.

2. Topalian SL, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.

3. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.

4. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.

5. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2018;18:183–194.

Immunotherapy for Cancer vs Cancer Vaccines

by: lim ju boo, alias lin ru wu (林 如 武)

This article is a simple version on the question about Immunotherapy for Cancer vs Cancer Vaccines.  It is written for ordinary medical doctors, biomedical scientists including patients with cancers who may be interested in other therapeutic options other than chemotherapies 

I shall write a much more technical version together with my research colleague later for oncologists and research scientists involved in cancer research

There are several major types of immunotherapy drugs used to treat cancer, generally classified by how they help the immune system fight cancer cells. The primary types include immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, treatment vaccines, and immunomodulators. 

Examples of the main types of immunotherapies.  

1. Immune Checkpoint Inhibitors. These are the most common type of immunotherapy. They block checkpoint proteins (like PD-1/PD-L1 and CTLA-4) that prevent T cells from destroying cancer cells.  

2. Adoptive Cell Therapy (T-cell transfer): This involves removing a patient's own T cells, modifying them in a lab to better recognize and kill cancer cells (such as CAR T-cell therapy), and returning them to the body.  

3. Monoclonal Antibodies (mAbs): Laboratory-made proteins designed to bind to specific targets on cancer cells, either flagging them for destruction or stopping them from growing. 

4. Antibody-Drug Conjugates (ADCs): A type of monoclonal antibody that is linked to a chemotherapy drug, allowing it to deliver the toxin directly to the cancer cell. 

5. Oncolytic Virus Therapy: Uses genetically modified viruses to infect and destroy cancer cells. 

6. Cancer Vaccines: Therapeutic vaccines that help the immune system recognize and attack specific antigens on cancer cells. 

7. Immunomodulators (Non-specific): These generally boost the immune system, including cytokines like interleukins and interferons, which help coordinate the immune response. 

As of 2023, there were over 11 FDA-approved immune checkpoint inhibitors (ICIs) covering more than 20 cancer types, with over 70 different immunotherapy drugs in clinical pipelines. 

For instance, Pembrolizumab (brand name Keytruda) is a widely used immunotherapy medication that helps the body's immune system fight cancer by blocking the PD-1/PD-L1 pathway. It is used to treat numerous advanced cancers, including melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, triple-negative breast cancer, cervical cancer, and others, often as a first-line treatment.  Key uses and indications for Pembrolizumab are, 1.  melanoma treats advanced, unresectable, or metastatic melanoma, and is used to prevent recurrence after surgery. 2. Lung Cancer (NSCLC). This is used in various stages, often as first-line treatment for metastatic disease, particularly when tumours express high levels of PD-L1. 3. Head and Neck Cancer. It is used for recurrent or metastatic squamous cell carcinoma. 4. Breast Cancer: Pembrolizumab treats high-risk early-stage and metastatic triple-negative breast cancer (TNBC). 4. Gynaecological / GI Cancers. It is used to treats cervical, endometrial, oesophageal, and gastric cancers. 5. Lymphoma / Other Solid Tumours Used for classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, and

tumours with specific genetic features (MSI-H or dMMR).

Mode of action -  It is a monoclonal antibody that inhibits the PD-1 protein on immune T-cells, allowing them to better recognize and kill cancer cells. It is given intravenously (through a vein), either alone or in combination with chemotherapy. It is also  approved for a wide variety of cancer types, often regardless of the tissue of origin, provided specific biomarkers are present. Treatment decisions are made by an oncologist  based on specific biomarkers (like PD-L1 expression) and the cancer type.

When I mentioned this casually in one of my WhatsApp chat group , a specialist doctor friend in the chat group asked if we can we use pembrolizumab to stimulate the auto immunity against cancer even in healthy individual who do not have cancer instead of using cancer vaccines

My answer to him is a straight -  NO. Here are my reasons.

Using pembrolizumab (Keytruda) in healthy individuals who do not have cancer, with the goal of stimulating immunity to prevent cancer instead of using cancer vaccines, is currently not an approved or standard medical practice. While some research is exploring the concept of "immuno-prevention" for high-risk, pre-cancerous conditions, treating healthy individuals with checkpoint inhibitors like pembrolizumab poses significant, often severe, risks to overall health. This approach is not used in healthy people because of these reasons: 

1. High Risk of Severe Autoimmunity
Pembrolizumab is an "immune checkpoint inhibitor." Its mechanism involves taking the "brakes" off the immune system (blocking the PD-1 receptor) so T-cells can attack cancer cells. A healthy person’s immune system is tightly regulated to prevent it from attacking its own body. By removing these brakes, pembrolizumab causes the immune system to attack healthy cells and tissues.

Then we need to consider the side effects of immunotherapy drugs They can lead to 1. severe or life-threatening autoimmune conditions, including pneumonitis (lung inflammation), colitis (bowel inflammation), hepatitis (liver damage), nephritis (kidney damage), and damage to endocrine glands. See link:

www.keytrudahcp.com

2. "Unmasking" Autoimmunity
In healthy individuals, the PD-1/PD-L1 pathway is crucial for maintaining tolerance to self-tissues. If this pathway is blocked, the immune system may attack organs, resulting in autoimmune diseases like Type 1 diabetes, thyroid problems, or severe arthritis.

3. Different Mechanisms: Vaccines vs. Inhibitors
Cancer Vaccines: These are designed to teach the immune system to recognize specific, foreign-looking antigens on cancer cells, providing a targeted response.
Pembrolizumab: This is a broad activator of T-cells. It does not teach the immune system to recognize cancer; it simply stops the immune system from stopping itself. If there is no cancer present, it has no specific target and primarily attacks healthy tissue.

4. Current Research on Immuno-prevention
Researchers are exploring "immuno-prevention" in very specific, high-risk scenarios, such as in patients with lung nodules that have begun to change but are not yet cancer. These are not "healthy individuals" but rather individuals with pre-cancerous conditions, and these treatments are performed within strictly controlled, experimental clinical trials.

No, it is not safe or effective to use pembrolizumab as a general, preventative, "vaccine-like" measure in healthy individuals. The potential risks.  Using pembrolizumab (Keytruda) in healthy individuals who do not have cancer, with the goal of stimulating immunity to prevent cancer instead of using cancer vaccines, is currently not an approved or standard medical practice.

While some research is exploring the concept of "immuno-prevention" for high-risk, pre-cancerous conditions, treating healthy individuals with checkpoint inhibitors like pembrolizumab poses significant, often severe, risks to overall health.

 

The Promise and the Limits of Cancer Vaccines: Between Scientific Hope and Biological Reality

I received this information about a Russian cancer vaccine sent to us through my WhatsApp chat group. It was sent to us by Ir. CK Cheong.

Let me quote what he sent to me - or rather to all of us in the WhatsApp. 

“the nightmare scenario for the US is here... Russia, not China, has developed a vaccine for cancer  China is preparing to approve Russia’s groundbreaking cancer vaccine, a development that could disrupt the $2.6 trillion Western oncology market. This vaccine, designed to target and train the immune system to attack cancer cells, represents a major shift from traditional treatments like chemotherapy and radiation. If widely adopted, it could transform how cancer is prevented and treated around the world. The economic implications are massive. Western pharmaceutical companies have long dominated cancer care with treatments generating billions in revenue annually. A safe and effective vaccine from Russia, endorsed and distributed by China, could challenge this dominance, making accessible, cost-effective cancer care available on a global scale and shifting the balance of the industry.”

 https://x.com/NextScience/status/2020145805877977296

Thank you Ir. CK Cheong for the above link. 

Let me explain  what I know about immunotherapy and cancer vaccines.

I shall follow up on this article with two more detailed research  papers  on the same subject - one I wrote on my own, the other together with a cancer immunologist. This would be of great interest to doctors and cancer patients alike if there are other options than the traditional chemotherapy. 

Let me deal with this one first. 

In recent weeks, a message circulating on social media and WhatsApp groups has generated considerable excitement. It claims that Russia has developed a groundbreaking “cancer vaccine” that could potentially disrupt the global oncology industry and even threaten the dominance of Western pharmaceutical companies. According to these reports, China is preparing to approve this vaccine, and if successful, it could transform cancer treatment worldwide by replacing conventional modalities such as chemotherapy and radiotherapy with a single, powerful immunological solution.

At first glance, such claims are understandably captivating. Cancer remains one of humanity’s greatest medical challenges, and any genuine breakthrough naturally inspires hope. However, a careful scientific analysis reveals that the reality is far more remote  and considerably less sensational, than the headlines suggest.

 It may be possible to train the immune system to recognize and attack cancer cells. This approach, known as immunotherapy, is a validated and active area of global cancer research. Russian researchers are currently developing a personalized mRNA-based therapeutic vaccine, which they claim could theoretically be adapted for many types of cancer. However, it is not a "universal" one-size-fits-all shot. While early pre-clinical animal trials showed promising results such as a 60–80% reduction in tumor size since human clinical trials are still in early stages or just beginning. The Russian claim refers to an experimental, personalized mRNA-based vaccine named Enteromix (or similar, details are limited) that is currently in early-stage clinical trials. The vaccine is designed to be personalized, using a patient's unique tumor profile (neoantigens) to create a tailored mRNA sequence that instructs the body's cells to produce proteins that the immune system will recognize as a threat and attack. This is a promising approach in personalized medicine. Russian officials have reported promising results from preclinical studies and early Phase 1 human trials, including significant tumor size reduction and a 100% immune response in some participants, with no serious side effects. Let me explain in technical details how it may work: The vaccine is therapeutic (designed to treat existing tumors) rather than preventive (designed to stop cancer before it starts). Its mechanism is based on the following process: 

 

1.             Tumor Passport Creation: Doctors extract a sample of a patient's tumor and use Artificial Intelligence (AI) to analyze its unique genetic profile.

 

2.             Neoantigen Identification: The AI identifies neoantigens, specific proteins or mutations found only on the cancer cells and not on healthy tissue.

 

3.             mRNA Synthesis: In about a week, scientists synthesize a custom mRNA sequence that carries the "blueprints" for these neoantigens.

 

4.             Immune Instruction: Once injected (typically via lipid nanoparticles), the mRNA instructs the patient’s own cells to produce these cancer-specific proteins.

 

5.             Targeted Attack: The immune system (specifically T-cells) recognizes these produced proteins as foreign threats and "learns" to hunt and destroy any original cancer cells that display them.

 

Current Development Status Target Cancers: Initial human trials, which began or are slated for late 2024 to 2025, focus on melanoma and small cell lung cancer. 

Technology Name: 

Some reports refer to a specific platform called Enteromix, while others highlight the broader mRNA work by the Gamaleya National Research Center (the developers of the Sputnik V COVID-19 vaccine). 

The Russian government has announced that once approved, the vaccine will be provided free of charge to Russian citizens under the national healthcare system. 

Let me explain the caution. International experts emphasize that while the tech is groundbreaking, the "100% success" claims reported by some state media are based on very small-scale or pre-clinical data and have not yet been verified through large-scale, peer-reviewed human trials. 

 

There are  other cancer vaccines too not just the Russian one currently in development, such as those from Moderna or BioNTech? However, as far as I know international medical experts emphasize that these are early-stage results based on small sample sizes. The claims of "100% success" or being "ready for use" are considered exaggerated by the global scientific community, which requires larger, independent, peer-reviewed Phase 2 and Phase 3 clinical trials to confirm safety and effectiveness before any wide-scale approval. 

The Promise and the Limits of Cancer Vaccines: Between Scientific Hope and Biological Reality

Immunotherapy: A Real and Rapidly Advancing Field

The core scientific principle behind these claims is not fiction. It is rooted in a legitimate and rapidly expanding discipline known as cancer immunotherapy, an approach that seeks to train the body’s own immune system to recognize and destroy malignant cells.

Unlike traditional treatments that directly target tumors with drugs or radiation, immunotherapy works indirectly by enhancing immune surveillance, particularly through T-cells. This concept has already yielded successful therapies, including immune checkpoint inhibitors and CAR-T cell therapy, which have revolutionized the management of certain cancers.

The Russian initiative belongs to this same scientific lineage.

The Russian mRNA Vaccine: What Is Actually Being Developed?

Russian researchers, particularly those associated with the Gamaleya National Research Center (the institute behind the Sputnik V COVID-19 vaccine), are developing an experimental, personalized mRNA-based therapeutic cancer vaccine. Some reports refer to the platform as Enteromix, though technical details remain limited and largely unpublished in peer-reviewed international journals.

Importantly, this is not a universal cancer vaccine. It is not designed to prevent cancer in healthy individuals, nor is it a one-size-fits-all cure. Rather, it is a personalized therapeutic vaccine, tailored specifically to each patient’s tumor.

How Such a Vaccine May Work (In Theory) Here are two links for the diagrams

National Cancer Institute – Cancer Vaccines Explained

https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-vaccines

Or even more refined:

A visual illustration of this process is available at the U.S. National Cancer Institute website:

https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-vaccines

The proposed mechanism is scientifically elegant and consistent with current research trends:

Tumor Profiling
A biopsy of the patient’s tumor is genetically sequenced, often with the aid of artificial intelligence.

 Neoantigen Discovery

Unique cancer-specific mutations (neoantigens) are identified, molecular signatures absent in normal cells.

Custom mRNA Design
Scientists synthesize a bespoke mRNA sequence encoding these neoantigens.

Immune Training
The mRNA is delivered into the body using lipid nanoparticles, instructing the patient’s own cells to produce these tumor antigens.

Targeted Immune Attack
T-cells are activated and trained to recognize and destroy cancer cells displaying those antigens.

In essence, the body becomes its own personalized cancer-fighting factory.

Current Evidence: Promising, but Preliminary

According to Russian sources, early pre-clinical studies in animals have demonstrated tumor reductions of up to 60–80%. Small Phase 1 human trials, mainly involving melanoma and small-cell lung cancer, have reportedly shown strong immune activation with minimal side effects.

However, from a scientific standpoint, these results remain exploratory rather than definitive. Phase 1 trials are designed primarily to assess safety, not effectiveness. Claims of “100% success” or “complete cures” are based on very small samples and lack independent international verification.

Without large-scale, randomized Phase 2 and Phase 3 trials published in reputable journals, such claims cannot be regarded as established medical evidence.

 Not a Russian Monopoly: A Global Scientific Effort

It is also crucial to recognize that Russia is not alone in this field. Similar personalized mRNA cancer vaccines are under development by major biotechnology companies, including Moderna and BioNTech. These programs follow nearly identical scientific principles and are likewise in early or mid-stage clinical trials.

Thus, what we are witnessing is not a geopolitical revolution in medicine, but rather a global convergence of scientific innovation driven by advances in genomics, immunology, and artificial intelligence.

 Scientific Hope Versus Biological Reality

The scientific foundations of cancer immunotherapy are solid and inspiring. There is no doubt that personalized vaccines will play an increasingly important role in oncology in the coming decades.

Yet it is equally important to remain realistic.

Cancer is not a single disease, but a vast family of genetically unstable, adaptive biological processes. Tumors evolve, mutate, and evade immune detection. What works spectacularly in one patient may fail entirely in another. The immune system itself is constrained by tolerance mechanisms designed to prevent autoimmunity.

From a broader biological and philosophical perspective, it may also be argued that complete freedom from disease is neither biologically nor existentially consistent with human life. Aging, degeneration, and mortality are deeply embedded in the fabric of living systems. Nature appears to prioritize reproduction, variation, and renewal over indefinite survival.

In that sense, medicine may continue to delay death, reduce suffering, and improve quality of life, but not abolish mortality itself.

My feeling is the Russian mRNA cancer vaccine represents a promising scientific experiment, not a proven cure. Its underlying principles are shared by leading research programs worldwide, and its early results, while encouraging, remain far from conclusive.

The true value of this development lies not in sensational headlines or economic speculation, but in its contribution to a growing body of knowledge that may one day transform cancer into a manageable, chronic condition rather than a fatal diagnosis.

Until then, cautious optimism, guided by rigorous science rather than political or commercial enthusiasm, remains the most intellectually honest stance.

To understand how a personalized cancer vaccine may work, it is helpful to imagine the immune system as a highly trained security force whose main problem is not weakness, but mis-identification. Cancer cells originate from our own tissues, so they often appear “normal” and escape immune detection.

The purpose of a cancer vaccine is therefore not to kill cancer directly, but to teach the immune system what the enemy looks like.

Step 1: Studying the Enemy (Tumor Profiling)

A small sample of the patient’s tumor is first removed through biopsy or surgery. This sample contains millions of cancer cells, each carrying genetic mutations that differ from normal cells.

Using advanced genetic sequencing (often assisted by artificial intelligence), scientists analyze these cancer cells in great detail to identify their unique molecular features.

Step 2: Finding the Cancer’s Fingerprints (Neoantigens)

Among all these mutations, researchers look for neoantigens,  abnormal proteins that exist only on cancer cells and not on healthy tissues.

These neoantigens act like fingerprints or facial features of the cancer. They are the most reliable markers that allow the immune system to distinguish malignant cells from normal ones.

Step 3: Writing the Immune “Instruction Manual” (mRNA Design)

Once the neoantigens are identified, scientists design a customized strand of messenger RNA (mRNA) that contains the genetic instructions for producing those exact cancer-specific proteins.

This mRNA is essentially a biological message that says:
“Here is what the cancer looks like. Learn this.”

Step 4: Teaching the Body (mRNA Injection)

The mRNA is injected into the patient, usually enclosed within microscopic lipid particles that protect it and help it enter cells.

Inside the body, normal cells temporarily read this mRNA and produce harmless copies of the cancer-specific proteins.

Importantly, no cancer is created — only the signature proteins of cancer are displayed.

Step 5: Immune Training (T-cell Activation)

The immune system now sees these abnormal proteins and recognizes them as foreign.

This activates specialized immune cells, especially T-lymphocytes, which begin to memorize these cancer signatures.

In effect, the immune system undergoes a form of vaccination training, similar to how it learns to recognize viruses.

Step 6: The Targeted Attack

Once trained, these T-cells circulate throughout the body searching for any real cancer cells displaying the same neoantigens.

When found, they bind to them and destroy them through immune mechanisms.

Thus, the immune system becomes a precision-guided internal weapon, capable of seeking out and eliminating cancer cells while sparing healthy tissues.

 

Why This Approach Is So Powerful (In Theory)

This method has three major advantages:

1.  Extreme specificity

Only cancer cells are targeted, minimizing damage to normal organs.

2. Personalization

Each vaccine is custom-built for each patient’s tumor.

3. Biological amplification

Once trained, the immune system can continue working long after the injection. In principle, this is one of the most intelligent and elegant strategies ever conceived in oncology.

 

Why It Still Faces Major Limitations

Despite its beauty, several biological challenges remain:

 Cancer mutates rapidly and may change its “appearance.”

Some tumours suppress immune activity.

Not all cancers present strong neoantigens.

Immune exhaustion may occur in advanced disease.

This is why to my personal understanding,  such vaccines work brilliantly in some patients and poorly in others, and why universal success remains unlikely.

A Deeper Reflection

In philosophical terms - a spiritual area I am always interested in - not just in medicine and science only -  this technology to me does not “defeat nature.”
It merely cooperates with nature, by enhancing the body’s existing defensive intelligence.

Medicine here is not creating immortality, but borrowing time from entropy,  delaying decline, reducing suffering, and improving quality of life, while remaining subject to the deeper biological laws of aging and mortality.

Having written and explained all that, my feeling is, I think the scientific principle is sound and part of a global effort in immunotherapy research, but the specific Russian vaccine's claims require further independent validation through rigorous, large-scale clinical trials. 

Let me conclude by saying I think we cannot be too confident about this Russian vaccine or any other vaccines against cancer because Nature too has its purpose to fight back in that we cannot remain here free from any disease, including cancer for us to continue to live here in this world forever. 

See my explanation here:

https://scientificlogic.blogspot.com/2026/02/why-must-it-be-necessary-for-us-to-age.html?m=1  

Some references (for further reading)

1.  Sahin U., Türeci Ö. Personalized vaccines for cancer immunotherapy. Science, 2018.

2. Waldman A.D. et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020.

3. Ott P.A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017.

4. Moderna Oncology Pipeline – mRNA Cancer Vaccines.

BioNTech Individualized Neoantigen Therapies (iNeST Program).